Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
Launched by EISAI CO., LTD. · Dec 1, 2010
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion criteria;
- • Patients diagnosed as Alzheimer's Disease by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
- • Patients diagnosed as mild or moderate Alzheimer's Disease, applicable to Functional Assessment Staging (FAST) score 4 or 5.
- • Exclusion criteria;
- • Patients who used Aricept within 3 months prior to dosing.
- • Patients registered this survey before.
- • Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a global pharmaceutical company headquartered in Japan, dedicated to the research, development, and commercialization of innovative therapeutics that address unmet medical needs. With a strong focus on neurology and oncology, Eisai leverages its extensive expertise in drug discovery and development to advance treatments that improve patient outcomes. Committed to the principles of transparency and collaboration, Eisai actively engages in clinical trials to evaluate the safety and efficacy of its products, ensuring that its research aligns with the highest ethical standards. Through its patient-centric approach, Eisai strives to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nagoya, Aichi, Japan
Niihama, Ehime, Japan
Sapporo, Hokkaido, Japan
Kanazawa, Ishikawa, Japan
Kashihara, Nara, Japan
Yufu, Oita, Japan
Izumisano, Osaka, Japan
Gifu, , Japan
Hiroshima, , Japan
Kyoto, , Japan
Nara, , Japan
Oita, , Japan
Chiba, , Japan
Fukuoka, , Japan
Osaka, , Japan
Shizuoka, , Japan
Suita, Osaka, Japan
Fukuoka, , Japan
Kagoshima, , Japan
Osaka, , Japan
Suita, Osaka, Japan
Okayama, , Japan
Kobe, Hyogo, Japan
Osakasayama, Osaka, Japan
Fukushima, , Japan
Hirosaki, Aomori, Japan
Fukuyama, Hiroshima, Japan
Hakodate, Hokkaido, Japan
Sendai, Miyagi, Japan
Ube, Yamaguchi, Japan
Niigata, , Japan
Kashiwa, Chiba, Japan
Sakura, Chiba, Japan
Yokohama, Kanagawa, Japan
Kurashiki, Okayama, Japan
Kochi, , Japan
Tsu, Mie, Japan
Shinjuku, Tokyo, Japan
Kyoto, , Japan
Himeji, Hyogo, Japan
Omuta, Fukuoka, Japan
Miyoshi, Hiroshima, Japan
Otake, Hiroshima, Japan
Nankoku, Kochi, Japan
Sakai, Osaka, Japan
Akita, , Japan
Toon, Ehime, Japan
Hamamatsu, Shizuoka, Japan
Amagasaki, Hyogo, Japan
Bunkyo, Tokyo, Japan
Hachioji, Tokyo, Japan
Itabashi, Tokyo, Japan
Nagoya, Aichi, Japan
Fukushima, , Japan
Matsuyama, Ehime, Japan
Kitakyushu, Fukuoka, Japan
Uji, Kyoto, Japan
Otaru, Hokkaido, Japan
Kawasaki, Kanagawa, Japan
Setagaya, Tokyo, Japan
Kure, Hiroshima, Japan
Anjo, Aichi, Japan
Sasebo, Nagasaki, Japan
Ikoma, Nara, Japan
Iruma, Saitama, Japan
Yamanashi, , Japan
Moriya, Ibaraki, Japan
Nakano, Tokyo, Japan
Daisen, Akita, Japan
Towada, Aomori, Japan
Ichihara, Chiba, Japan
Iyo, Ehime, Japan
Ukiha, Fukuoka, Japan
Iwaki, Fukushima, Japan
Fujioka, Gumma, Japan
Nayoro, Hokkaido, Japan
Obihiro, Hokkaido, Japan
Sunagawa, Hokkaido, Japan
Akashi, Hyogo, Japan
Kita, Kagawa, Japan
Mitoyo, Kagawa, Japan
Ebina, Kanagawa, Japan
Yokosuka, Kanagawa, Japan
Suzuka, Mie, Japan
Yokkaichi, Mie, Japan
Iida, Nagano, Japan
Matsumoto, Nagano, Japan
Okaya, Nagano, Japan
Saiki, Oita, Japan
Kaizuka, Osaka, Japan
Matsubara, Osaka, Japan
Fukaya, Saitama, Japan
Hanno, Saitama, Japan
Koshigaya, Saitama, Japan
Sayama, Saitama, Japan
Adachi, Tokyo, Japan
Katsushika, Tokyo, Japan
Machida, Tokyo, Japan
Meguro, Tokyo, Japan
Minato, Tokyo, Japan
Toshima, Tokyo, Japan
Kurayoshi, Tottori, Japan
Nanto, Toyama, Japan
Kinokawa, Wakayama, Japan
Tendo, Yamagata, Japan
Hagi, Yamaguchi, Japan
Shunan, Yamaguchi, Japan
Matsuyama, Ehime, Japan
Sendai, Miyagi, Japan
Mizunami, Gifu, Japan
Aioi, Hyogo, Japan
Kitamorokata, Miyazaki, Japan
Masuda, Shimane, Japan
Taito, Tokyo, Japan
Patients applied
Trial Officials
Shoya Yamakawa
Study Director
Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials